WO1998050065A3 - The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein - Google Patents

The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein Download PDF

Info

Publication number
WO1998050065A3
WO1998050065A3 PCT/EP1998/001951 EP9801951W WO9850065A3 WO 1998050065 A3 WO1998050065 A3 WO 1998050065A3 EP 9801951 W EP9801951 W EP 9801951W WO 9850065 A3 WO9850065 A3 WO 9850065A3
Authority
WO
WIPO (PCT)
Prior art keywords
active substances
influencing
administration
controlling
device used
Prior art date
Application number
PCT/EP1998/001951
Other languages
German (de)
French (fr)
Other versions
WO1998050065A2 (en
Inventor
Marion Sangster Eckmiller
Original Assignee
Marion Sangster Eckmiller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marion Sangster Eckmiller filed Critical Marion Sangster Eckmiller
Priority to AU76417/98A priority Critical patent/AU7641798A/en
Priority to EP98924097A priority patent/EP0980256A2/en
Priority to CA002288631A priority patent/CA2288631A1/en
Publication of WO1998050065A2 publication Critical patent/WO1998050065A2/en
Publication of WO1998050065A3 publication Critical patent/WO1998050065A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Abstract

The invention relates to the use of an active substance influencing the calcium homeostasis of cells to treat degeneration of sensory cells and adjacent cells.
PCT/EP1998/001951 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein WO1998050065A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU76417/98A AU7641798A (en) 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular areaof sensory cells and method for controlling the administration of active substa nces and device used therein
EP98924097A EP0980256A2 (en) 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein
CA002288631A CA2288631A1 (en) 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1997118826 DE19718826A1 (en) 1997-05-05 1997-05-05 Use of biologically active agents to influence the extracellular space of sensory cells and methods for drug administration control
DE19718826.5 1997-05-05

Publications (2)

Publication Number Publication Date
WO1998050065A2 WO1998050065A2 (en) 1998-11-12
WO1998050065A3 true WO1998050065A3 (en) 1999-06-10

Family

ID=7828596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/001951 WO1998050065A2 (en) 1997-05-05 1998-04-02 The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein

Country Status (5)

Country Link
EP (1) EP0980256A2 (en)
AU (1) AU7641798A (en)
CA (1) CA2288631A1 (en)
DE (1) DE19718826A1 (en)
WO (1) WO1998050065A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4422894B2 (en) 1998-03-05 2010-02-24 千寿製薬株式会社 Pharmaceutical composition for prevention and treatment of diseases caused by ocular fundus tissue cell damage
FR2784030B1 (en) * 1998-10-02 2002-12-20 Inst Nat Sante Rech Med USE OF CALCIUM AND / OR CGMP-DEPENDENT CHANNEL BLOCKERS FOR THE TREATMENT OF RETINE CONDITIONS
US6864243B1 (en) * 2000-05-12 2005-03-08 Inspire Pharmaceuticals, Inc. Method for treating retinal degeneration with purinergic receptor agonists
JP4758641B2 (en) * 2003-12-12 2011-08-31 千寿製薬株式会社 α-Ketoamide derivative, process for producing the same, and use thereof
US7491705B2 (en) 2003-12-12 2009-02-17 Senju Pharmaceutical Co., Ltd. Alpha-ketoamide derivative, and production method and use thereof
DE102009056597A1 (en) * 2009-12-02 2011-06-09 Tobias Brockmann Use of flavin derivatives and their salts for preparing a medicament for the treatment of pathologies of the internal limiting membrane (ILM), and the flavin derivative is riboflavin or roseoflavin
AU2017312499B2 (en) 2016-08-19 2023-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration
WO2020036658A2 (en) * 2018-04-27 2020-02-20 The Johns Hopkins University Drugs promoting retinal rod photoreceptor survival

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995057A (en) * 1974-04-19 1976-11-30 Wilhelm Horrmann Ophthalmological method
US4188394A (en) * 1978-05-08 1980-02-12 Nelson Research & Development Company Ophthalmic composition and method of use
JPS5718609A (en) * 1980-07-08 1982-01-30 Senjiyu Seiyaku Kk Intraocular hypotensor
JPS5732229A (en) * 1980-08-05 1982-02-20 Eiji Sakata Preventing agent against kinesia
JPS57130923A (en) * 1981-02-07 1982-08-13 Eiji Sakata Remedy and preventive for vertigo
SU1297862A1 (en) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Agent for treatment of pigment degeneration of retina
WO1990006123A1 (en) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
WO1990012590A1 (en) * 1989-04-14 1990-11-01 State Of Oregon, State Board Of Higher Education, Oregon Health Sciences University Treatment of ocular disease by modulation of matrix metalloproteinases and their inhibitor
EP0430539A2 (en) * 1989-11-22 1991-06-05 Visionex, Inc. Ocular implants
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
EP0485232A1 (en) * 1990-11-08 1992-05-13 Unitika Ltd. Neovascularisation inhibitors
WO1992007580A1 (en) * 1990-11-05 1992-05-14 Biosource Genetics Corporation Therapeutic uses of melanin
JPH04182432A (en) * 1990-11-19 1992-06-30 Toshio Tanaka Calcium-dependent cyclic nucleotide phosphodiesterase inhibitor
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
WO1993015608A1 (en) * 1992-02-14 1993-08-19 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
CN1077092A (en) * 1992-04-10 1993-10-13 张勇 A kind of preparation method of beverage caring for eyes
CN1082896A (en) * 1992-07-18 1994-03-02 苏州第六制药厂 Process for preparing dizzy-stopping suppository
JPH06234645A (en) * 1993-02-09 1994-08-23 Toagosei Chem Ind Co Ltd Vasculatization inhibitor
WO1994025020A1 (en) * 1993-04-28 1994-11-10 Pharmacia Ab Method and means for inhibiting posterior capsule opacification
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
WO1995015958A1 (en) * 1993-12-08 1995-06-15 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
JPH07215892A (en) * 1994-01-27 1995-08-15 Sumitomo Pharmaceut Co Ltd Medicinal composition for curing spontaneouse deafness
CN1108539A (en) * 1994-03-16 1995-09-20 吴生武 Eyedrops for curing myopia
WO1995034302A2 (en) * 1994-06-16 1995-12-21 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
WO1996030366A1 (en) * 1995-03-28 1996-10-03 Ferrer Internacional, S.A. Polymorphs a and b of 1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl) propyl]piperazine
WO1996036334A1 (en) * 1995-05-19 1996-11-21 University Of East Anglia Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors
WO1996041805A1 (en) * 1993-12-08 1996-12-27 Alcon Laboratories, Inc. Dihydro pyridines having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
WO1996041638A1 (en) * 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
CA2188817A1 (en) * 1995-10-25 1997-04-26 Chiho Fukiage Angiogenesis inhibitor
WO1997029756A1 (en) * 1996-02-21 1997-08-21 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
WO1997034586A2 (en) * 1996-03-22 1997-09-25 Cytotherapeutics, Inc. Device and method for treating ophthalmic diseases
WO1998001128A1 (en) * 1996-07-05 1998-01-15 Mendes S.R.L. Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
WO1998018485A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. The use of calpain inhibitors to treat ocular neural pathology
EP0848952A1 (en) * 1996-12-03 1998-06-24 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of lower alkanoyl l-carnitines to produce a medicament suitable for the therapeutic treatment of retinopathies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH658595A5 (en) * 1983-08-17 1986-11-28 Inst Khim Fiz An Sssr RETINO PROTECTOR FOR THE TREATMENT OF EYE DISEASES.
WO1993010798A1 (en) * 1991-12-04 1993-06-10 Uab Research Foundation Monoclonal antibody directed against g-cam and method of using it
US5252568A (en) * 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with loxapine
US5266580A (en) * 1992-01-24 1993-11-30 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration with droperidol

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995057A (en) * 1974-04-19 1976-11-30 Wilhelm Horrmann Ophthalmological method
US4188394A (en) * 1978-05-08 1980-02-12 Nelson Research & Development Company Ophthalmic composition and method of use
SU1297862A1 (en) * 1980-07-03 1987-03-23 Институт цитологии и генетики СО АН СССР Agent for treatment of pigment degeneration of retina
JPS5718609A (en) * 1980-07-08 1982-01-30 Senjiyu Seiyaku Kk Intraocular hypotensor
JPS5732229A (en) * 1980-08-05 1982-02-20 Eiji Sakata Preventing agent against kinesia
JPS57130923A (en) * 1981-02-07 1982-08-13 Eiji Sakata Remedy and preventive for vertigo
WO1990006123A1 (en) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Therapeutic use of calcium entry blockers in retinal or optic nerve dysfunction
WO1990006118A1 (en) * 1988-12-05 1990-06-14 Houston Biotechnology Incorporated Therapeutic use of dihydropyrimidones and benzazepine and benzothiazepine derivatives in retinal or optic nerve dysfunction
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
WO1990012590A1 (en) * 1989-04-14 1990-11-01 State Of Oregon, State Board Of Higher Education, Oregon Health Sciences University Treatment of ocular disease by modulation of matrix metalloproteinases and their inhibitor
US5156852A (en) * 1989-04-20 1992-10-20 La Haye Laboratories, Inc. Composition and method for combating macular degeneration
EP0430539A2 (en) * 1989-11-22 1991-06-05 Visionex, Inc. Ocular implants
WO1992007580A1 (en) * 1990-11-05 1992-05-14 Biosource Genetics Corporation Therapeutic uses of melanin
EP0485232A1 (en) * 1990-11-08 1992-05-13 Unitika Ltd. Neovascularisation inhibitors
JPH04182432A (en) * 1990-11-19 1992-06-30 Toshio Tanaka Calcium-dependent cyclic nucleotide phosphodiesterase inhibitor
WO1993015608A1 (en) * 1992-02-14 1993-08-19 Regeneron Pharmaceuticals, Inc. Prevention of retinal injury and degeneration by specific factors
CN1077092A (en) * 1992-04-10 1993-10-13 张勇 A kind of preparation method of beverage caring for eyes
CN1082896A (en) * 1992-07-18 1994-03-02 苏州第六制药厂 Process for preparing dizzy-stopping suppository
JPH06234645A (en) * 1993-02-09 1994-08-23 Toagosei Chem Ind Co Ltd Vasculatization inhibitor
WO1994025020A1 (en) * 1993-04-28 1994-11-10 Pharmacia Ab Method and means for inhibiting posterior capsule opacification
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
WO1996041805A1 (en) * 1993-12-08 1996-12-27 Alcon Laboratories, Inc. Dihydro pyridines having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
WO1995015958A1 (en) * 1993-12-08 1995-06-15 Alcon Laboratories, Inc. Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
JPH07215892A (en) * 1994-01-27 1995-08-15 Sumitomo Pharmaceut Co Ltd Medicinal composition for curing spontaneouse deafness
CN1108539A (en) * 1994-03-16 1995-09-20 吴生武 Eyedrops for curing myopia
WO1995034302A2 (en) * 1994-06-16 1995-12-21 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
WO1996030366A1 (en) * 1995-03-28 1996-10-03 Ferrer Internacional, S.A. Polymorphs a and b of 1-(diphenylmethyl)-4-[3-(2-phenyl-1,3-dioxolan-2-yl) propyl]piperazine
WO1996036334A1 (en) * 1995-05-19 1996-11-21 University Of East Anglia Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors
WO1996041638A1 (en) * 1995-06-13 1996-12-27 Sanofi Winthrop, Inc. Calpain inhibitors for the treatment of neurodegenerative diseases
CA2188817A1 (en) * 1995-10-25 1997-04-26 Chiho Fukiage Angiogenesis inhibitor
EP0771565A2 (en) * 1995-10-25 1997-05-07 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
WO1997029756A1 (en) * 1996-02-21 1997-08-21 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
WO1997034586A2 (en) * 1996-03-22 1997-09-25 Cytotherapeutics, Inc. Device and method for treating ophthalmic diseases
WO1998001128A1 (en) * 1996-07-05 1998-01-15 Mendes S.R.L. Use of l-acetylcarnitine, l-isovalerylcarnitine, l-propionylcarnitine for increasing the levels of igf-1
WO1998018485A1 (en) * 1996-10-31 1998-05-07 Alcon Laboratories, Inc. The use of calpain inhibitors to treat ocular neural pathology
EP0848952A1 (en) * 1996-12-03 1998-06-24 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Use of lower alkanoyl l-carnitines to produce a medicament suitable for the therapeutic treatment of retinopathies

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
BENNETT J. ET AL: "Photoreceptor Cell Rescue in Retinal Degeneration (rd) Mice by In Vivo Gene Therapy", NATURE MEDICINE, vol. 2, no. 6, 1996, pages 649 - 654, XP002088221 *
DATABASE EPODOC EPO; 13 October 1993 (1993-10-13), YONG ZHANG: "Preparation of beverage caring for eyes", XP002076671 *
DATABASE EPODOC EPO; 2 March 1994 (1994-03-02), ZHAOQING ZHU: "Process for preparing dizzy-stopping suppository", XP002076672 *
DATABASE EPODOC EPO; 20 September 1995 (1995-09-20), SHENGWU WU: "Eyedrops for curing myopia", XP002076670 *
DATABASE WPI Section Ch Week 8210, Derwent World Patents Index; Class A96, AN 82-18654E, XP002088226 *
DATABASE WPI Section Ch Week 8238, Derwent World Patents Index; Class B05, AN 82-80006E, XP002088224 *
DATABASE WPI Section Ch Week 8741, Derwent World Patents Index; Class B02, AN 87-290829, XP002076673 *
DATABASE WPI Section Ch Week 9232, Derwent World Patents Index; Class B06, AN 92-265116, XP002088225 *
DATABASE WPI Section Ch Week 9438, Derwent World Patents Index; Class B02, AN 94-307573, XP002088223 *
DATABASE WPI Section Ch Week 9542, Derwent World Patents Index; Class B04, AN 95-323471, XP002088222 *
LI J. ET AL: "Amelioration of Retinal Photic Injury by a combination of Flunarizine and Dimethylurea", EXPERIMENTAL EYE RESEARCH, vol. 56, no. 1, 1993, pages 71 - 78, XP002088220 *
MEDLINE, AN 72009827 *
MIZUKOSHI K. ET AL: "Clinical Evaluation of Medical Treatment for Meniere's Disease, using a Double-Blind Controlled Study", AMERICAN JOURNAL OF OTOLOGY, vol. 9, no. 5, 1988, pages 418 - 422, XP000654235 *
PATENT ABSTRACTS OF JAPAN vol. 006, no. 102 (C - 107) 11 June 1982 (1982-06-11) *
POTAPOV I.I. ET AL: "Therapy of Meniere's disease and otogenic vestibular disorders by means of intravenous injection of sodium hydrogencarbonate", VESTNIK OTORINOLARINGOLOGII, vol. 33, no. 3, 1971, pages 40 - 44 *
PROSDOCIMO G ET AL: "EFFETTO DELLA L-ACETILCARNITINA SULLA SOGLIA DI SENSIBILITA MACULARE IN PAZIENTI AFFETTI DA DEGENERATZIONE MACULARE SENILE NON ESSUDATIVA. NOTA PRELIMINARE", BOLLETTINO DI OCULISTICA, vol. 67, no. 4, 1988, pages 609 - 612, XP002058278 *
PROSDOCIMO G ET AL: "MIGLIORAMENTO DELLE PRESTAZIONI FUNZIONALI DELL'OCCHIO SENILE DOPO TERAPIA CON L-ACETILCARNITINA", BOLLETTINO DI OCULISTICA, vol. 70, no. 1, 1991, pages 57 - 61, XP002058277 *
RASCOL O. ET AL: "Antivertigo Medications and Drug-Induced Vertigo", DRUGS, vol. 50, no. 5, 1995, pages 777 - 791, XP002088219 *
VAN BOCKXMEER F.M. ET AL: "Taxol for the Treatment of Proliferative Vitreoretinopathy", INVESTIGATIVE OPHTHALMOLOGY AND VISUAL SCIENCE, vol. 26, no. 8, 1985, pages 1140 - 1147, XP002088218 *
WRIGHT J. V. ET AL: "Improvement of vision in macular degeneration associated with intravenous zinc and selenium therapy: two cases", J. NUTR. MED., vol. 1, no. 2, 1990, pages 133 - 138, XP002076668 *

Also Published As

Publication number Publication date
WO1998050065A2 (en) 1998-11-12
DE19718826A1 (en) 1998-11-12
CA2288631A1 (en) 1998-11-12
AU7641798A (en) 1998-11-27
EP0980256A2 (en) 2000-02-23

Similar Documents

Publication Publication Date Title
DE69830095D1 (en) Pharmaceutical, cosmetic or dermo-pharmaceutical patch for the administration of several different active substances
AU1610495A (en) Monitoring water treatment agent in-system concentration and regulating dosage
BR9710362A (en) Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound
AU3866097A (en) Naphtholactams and lactones as bone morphogenetic protein active agents
EE200000065A (en) Aerosol formulations containing biologically active macromolecules and water, and method for their preparation
DE69807634D1 (en) MEDICAL DEVICE FOR THE ADMINISTRATION OF THERAPEUTIC ACTIVE SUBSTANCES
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
PL321898A1 (en) Application of inorganic aerogles in pharmaceutics
AU7098698A (en) System of implantable devices for monitoring and/or affecting body parameters
ZA9811799B (en) Solid galenic form of the controlled release tablet type for the instant and then prolonged release of one or more active substances
BG103552A (en) Therapeutical forms
HUP9902867A3 (en) Therapeutic use of vegf protein or nucleic acid coding same and implant, especially for the treatment of intimal hyperplasia
HUP0105058A2 (en) Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress
DE69806801D1 (en) GALENIC PREPARATION FOR THE PREVENTION AND TREATMENT OF HEPATOCARCINOMA
DK0948340T3 (en) Biologically active substances, processes for their preparation and compounds with their contents
ATE249819T1 (en) PREPARATIONS FOR EXTERNAL USE FOR THE TREATMENT OF DERMATOSES
WO1997003188A3 (en) Use of mp52 or mp121 for treating and preventing diseases of the nervous system
ATE442184T1 (en) DEVICE FOR THE IONTOPHORETIC, TRANSDERMAL ADMINISTRATION OF FENTANYL AND SUFENTANIL
WO1998050065A3 (en) The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein
EP0960885A4 (en) Depsipeptides and drugs containing the same as the active ingredient
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
DE69825319D1 (en) PREPARATION FOR THE PREVENTION AND TREATMENT OF INFLAMMATION
EP0744176A3 (en) Methods for inhibiting bone loss
AU7595298A (en) Azolidinediones useful for the treatment of diabetes, dyslipidemia and hy pertension
PL330597A1 (en) Transcutaneous systems containing two active ingredients in separate compartments, method of obtaining them and their application as therapeutic agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GM GW HU IL JP KE KG KP KR KZ LC LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TT UA US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GM GW HU IL JP KE KG KP KR KZ LC LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TT UA US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1998924097

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2288631

Country of ref document: CA

Ref country code: CA

Ref document number: 2288631

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09423333

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998924097

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998547652

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998924097

Country of ref document: EP